항체 생산 시장은 2024-2031년간 연평균 11.4%의 연평균 복합 성장률(CAGR)로 2031년까지 583억 5,000만 달러에 달할 것으로 예상되며, 2차 및 1차 조사를 통해 시장 시나리오를 상세하게 분석한 후 주요 산업 촉진요인, 시장 성장 억제요인, 시장 기회, 시장 성장 성장 촉진요인, 과제 및 동향을 조사했습니다. 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회, 시장 성장 촉진요인 및 과제, 동향에 대해 고찰했습니다.
항체 생산 시장의 성장은 표적 항체에 대한 수요 증가, 제약 및 생명공학 기업의 R&D 투자 증가, 암 및 자가면역질환의 유병률 증가, 면역 측정 방법의 활용 증가, 바이오프로세스 기술의 발전 등에 의해 이루어지고 있습니다. 그러나 높은 항체 생산 비용과 엄격한 규제 프레임워크가 시장 성장을 저해하는 요인으로 작용하고 있습니다.
또한, 임상시험 및 의학 연구에서의 항체 사용 확대, 개발도상국에서의 큰 잠재력, 감염성 질환의 위험과 확산 증가는 이 시장에서 사업을 운영하는 기업들에게 성장 기회를 제공할 것으로 예상됩니다. 하지만, 단클론 항체의 복잡한 특성은 시장 이해관계자들에게 도전이 될 수 있습니다.
(주 : 주요 5개사의 SWOT 분석을 제공 예정)
Antibody Production Market by Product [Bioreactors (Single-use, Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers, Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit], Process [Downstream, Upstream] - Global Forecast to 2031
The antibody production market is projected to reach $58.35 billion by 2031, at a CAGR of 11.4% from 2024 to 2031. After secondary and primary research and an in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, opportunities, challenges, and trends.
The growth of the antibody production market is driven by the growing demand for targeted antibodies, increasing investments in R&D by pharma & biotech companies, the growing prevalence of cancer and autoimmune diseases, the increasing use of immunoassays, and advancements in bioprocessing technologies. However, the high costs of antibody production and stringent regulatory frameworks restrain the growth of this market.
Furthermore, the growing applications of antibodies in clinical trials and medical research, significant potential in developing countries, and the growing risk and prevalence of infectious diseases are expected to generate growth opportunities for the players operating in this market. However, the complex nature of monoclonal antibodies is a challenge for market stakeholders.
Based on product, the antibody production market is segmented into instruments, consumables, and software. In 2024, the instruments segment is expected to account for the largest share of the antibody production market. The need for high-volume and scalable production of antibodies for commercial use, the need for separation, purification, and isolation of antibodies, and the growing need for mass production of antibodies for therapeutic applications are major factors contributing to the segment's large share.
Based on antibody type, the antibody production market is segmented into monoclonal antibodies, polyclonal antibodies, antibody segments, and recombinant antibodies. The monoclonal antibodies segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the growing applications of monoclonal antibodies in the treatment of diseases and disorders, the growing use of monoclonal antibodies for cancer treatment, and the increasing focus of pharmaceutical & biotechnology companies on the development of monoclonal antibody-based therapeutics.
Based on source, the antibody production market is segmented into mice, rabbits, and other sources. In 2024, the mice segment is expected to account for the largest share of the antibody production market. Due to the availability, low cost, and quick production time for mouse mAbs, humanization of mouse mAbs has been implemented on a large scale. Furthermore, mouse husbandry is easier than rabbit husbandry, and the genetic approaches to engineering antibodies through recombinant technologies are more established for mice than for other animals, such as rabbits, making mice a preferred choice for antibody production.
Based on process, the antibody production market is segmented into upstream and downstream. In 2024, the downstream segment is expected to account for the larger share of the antibody production market. The segment's large share can be attributed to the high preference for downstream processing as it is used for the recovery and purification of biosynthetic products, including antibodies from natural sources such as animal or plant tissue or fermentation broth, including the recycling of salvageable components and the proper treatment and disposal of waste.
Based on end user, the antibody production market is segmented into pharmaceutical & biotechnology companies, clinical research organizations & contract development & manufacturing organizations, and other end users. The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is driven by the expansion of antibody manufacturing facilitates, increasing R&D investments by pharma & biotech companies, the growing prevalence of chronic & infectious diseases, and the need to develop antibody-based therapeutics for these diseases. In addition, initiatives by pharma and biotech companies to launch antibody-based therapeutics are further expected to drive the segment's growth.
An in-depth analysis of the geographical scenario in the antibody production market provides detailed qualitative and quantitative insights about five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the antibody production market, followed by Europe and Asia-Pacific. Technological advancements in bioprocessing, the high number of industry-academia collaborations for research & development of antibodies, the high prevalence of chronic diseases, and the high demand for biologics are expected to support North America's largest share.
The key companies operating in the antibody production market include Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), and Infors AG (Switzerland).
Antibody Production Market Assessment-by Product
(Note: Other instruments include shakers, mixers, incubators, sterilizers, centrifuges, and bioprocessing containers.)
(Note: Other consumables include membrane adsorbers, cell disruption reagents, pipettes, syringes, vials, closures, tubing, connectors, and sensors.)
Antibody Production Market Assessment-by Antibody Type
Antibody Production Market Assessment-by Source
(Note: Other sources include goats, sheep, and chicken.)
Antibody Production Market Assessment-by Process
Antibody Production Market Assessment-by End User
Antibody Production Market Assessment-by Geography
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)